drugset / Trial / NCT00994890
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
RandomizedParallel-groupDouble-blindOther
Summary
This study will investigate the safety of three fixed dose levels of tanezumab (2.5 mg, 5 mg, and 10 mg) administered at an 8-week interval by subcutaneous injection multiple (7) times during the study treatment period.
Timeline
- Start
- 2009-11-17
- Primary completion
- 2010-12-07
- Completion
- 2011-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tanezumab | Monoclonal antibody | 2.5 mg | Subcutaneous |
| Subject | Tanezumab | Monoclonal antibody | 5 mg | Subcutaneous |
| Subject | Tanezumab | Monoclonal antibody | 10 mg | Subcutaneous |